CureVac COVID-19 vaccine hits just 48% efficacy in final analysis
Fox News
German biotech company CureVac announced its COVID-19 vaccine demonstrated 48% efficacy against COVID-19 of any severity in a final readout of late-stage trial data.
Results in older age groups were inconclusive. Further findings suggested variants of concern (VOC) were behind the majority of COVID-19 cases in the late-stage trial, with just 3% of cases tied to the original strain. The low efficacy comes in contrast to Pfizer and Moderna's mRNA COVID-19 vaccines with over 90% efficacy and only somewhat diminished protection in the face of viral variants.More Related News